MCID: GLL017
MIFTS: 46

Gallbladder Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gallbladder Adenocarcinoma

MalaCards integrated aliases for Gallbladder Adenocarcinoma:

Name: Gallbladder Adenocarcinoma 12 14 69
Adenocarcinoma of the Gallbladder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3500
NCIt 46 C9166
UMLS 69 C0279651

Summaries for Gallbladder Adenocarcinoma

Disease Ontology : 12 A gallbladder carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Gallbladder Adenocarcinoma, also known as adenocarcinoma of the gallbladder, is related to adenocarcinoma of the gallbladder and extrahepatic biliary tract and gallbladder pleomorphic giant cell adenocarcinoma, and has symptoms including abdominal pain An important gene associated with Gallbladder Adenocarcinoma is MUC2 (Mucin 2, Oligomeric Mucus/Gel-Forming), and among its related pathways/superpathways are Signaling by ERBB2 and Proteoglycans in cancer. The drugs Oxaliplatin and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include liver, pancreas and colon, and related phenotypes are Decreased viability with paclitaxel and Decreased viability with paclitaxel

Related Diseases for Gallbladder Adenocarcinoma

Diseases related to Gallbladder Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma of the gallbladder and extrahepatic biliary tract 12.2
2 gallbladder pleomorphic giant cell adenocarcinoma 11.1
3 adenocarcinoma 10.6
4 breast intraductal proliferative lesion 10.5 EGFR ERBB2
5 intracystic papillary adenoma 10.4 EGFR ERBB2
6 progesterone-receptor negative breast cancer 10.4 EGFR ERBB2
7 breast scirrhous carcinoma 10.4 EGFR ERBB2
8 tumor suppressor gene on chromosome 11 10.4 EGFR ERBB2
9 oncocytic breast carcinoma 10.4 EGFR ERBB2
10 breast adenoid cystic carcinoma 10.4 EGFR ERBB2
11 breast squamous cell carcinoma 10.4 EGFR ERBB2
12 microglandular adenosis 10.4 EGFR ERBB2
13 luminal breast carcinoma 10.4 EGFR ERBB2
14 acneiform dermatitis 10.4 EGFR ERBB2
15 inflammatory breast carcinoma 10.4 EGFR ERBB2
16 lipid-rich carcinoma 10.4 EGFR ERBB2
17 adenosquamous cell lung carcinoma 10.3 EGFR ERBB2
18 tuberculous salpingitis 10.3 ERBB2 MYB
19 uterine carcinosarcoma 10.3 EGFR ERBB2
20 primary peritoneal carcinoma 10.3 EGFR ERBB2
21 mammary paget's disease 10.3 EGFR ERBB2
22 breast metaplastic carcinoma 10.3 EGFR ERBB2
23 hidradenocarcinoma 10.2 EGFR ERBB2 MUC2
24 tubular adenocarcinoma 10.2 EGFR ERBB2 MUC2
25 small intestinal adenocarcinoma 10.2 EGFR ERBB2 MUC2
26 mucoepidermoid carcinoma 10.2 EGFR ERBB2 MUC2
27 gastrointestinal system cancer 10.2 EGFR ERBB2 MUC2
28 cell type cancer 10.2 EGFR ERBB2 MUC2
29 gallbladder cancer 10.2 EGFR ERBB2 MUC2
30 papillary adenocarcinoma 10.1 ERBB2 MUC2
31 pancreatic mucinous cystadenoma 10.1 EZH2 MUC2
32 pre-malignant neoplasm 10.1 EGFR ERBB2
33 cholecystitis 10.0
34 signet ring cell adenocarcinoma 10.0 MUC2 SRC
35 colloid carcinoma of the pancreas 10.0 MUC2 PSCA
36 squamous cell carcinoma, head and neck 9.9 EGFR ERBB2 SRC
37 xanthogranulomatous cholecystitis 9.9
38 mucinous adenocarcinoma 9.9 EGFR MUC2
39 lung cancer susceptibility 3 9.9 EGFR ERBB2 SRC
40 glioblastoma multiforme 9.9 EGFR ERBB2 MTDH
41 reproductive organ cancer 9.8 EGFR ERBB2 PSCA
42 transitional cell carcinoma 9.8 EGFR ERBB2 PSCA
43 leukemia, chronic lymphocytic 2 9.7
44 fibrosis of extraocular muscles, congenital, 1 9.7
45 hypercalcemia, infantile, 1 9.7
46 leukemia, chronic lymphocytic 9.7
47 gallbladder disease 1 9.7
48 gastrointestinal stromal tumor 9.7
49 pulmonary hypertension 9.7
50 leukemia 9.7

Graphical network of the top 20 diseases related to Gallbladder Adenocarcinoma:



Diseases related to Gallbladder Adenocarcinoma

Symptoms & Phenotypes for Gallbladder Adenocarcinoma

UMLS symptoms related to Gallbladder Adenocarcinoma:


abdominal pain

GenomeRNAi Phenotypes related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 8.92 EGFR ERBB2 SRC
2 Decreased viability with paclitaxel GR00179-A-3 8.92 EGFR

MGI Mouse Phenotypes related to Gallbladder Adenocarcinoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.95 EGFR MUC2 MYB ERBB2 EZH2 MCAM
2 hematopoietic system MP:0005397 9.92 EGFR MUC2 MYB PSCA EZH2 SRC
3 endocrine/exocrine gland MP:0005379 9.91 MUC2 MYB ERBB2 EZH2 SRC MTDH
4 immune system MP:0005387 9.86 EGFR MUC2 MYB PSCA EZH2 SRC
5 integument MP:0010771 9.63 EGFR MYB ERBB2 EZH2 SRC MTDH
6 neoplasm MP:0002006 9.5 ERBB2 PSCA EZH2 SRC MTDH EGFR
7 normal MP:0002873 9.1 EGFR MYB ERBB2 PSCA EZH2 MTDH

Drugs & Therapeutics for Gallbladder Adenocarcinoma

Drugs for Gallbladder Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
2
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
3
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
4 Antimetabolites Phase 3,Phase 2,Phase 1
5 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
6 Anti-Infective Agents Phase 3,Phase 2,Phase 1
7 Antiviral Agents Phase 3,Phase 2,Phase 1
8 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
9 Liver Extracts Phase 3,Phase 2,Phase 1
10
Bevacizumab Approved, Investigational Phase 2 216974-75-3
11
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
12
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
13
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
14
Melphalan Approved Phase 2 148-82-3 460612 4053
15
Pancrelipase Approved, Investigational Phase 2,Phase 1 53608-75-6
16
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
18
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
19
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
20 Pancreatic Polypeptide Investigational Phase 2 59763-91-6
21 Angiogenesis Inhibitors Phase 2
22 Angiogenesis Modulating Agents Phase 2
23
Erlotinib Hydrochloride Phase 2,Phase 1 183319-69-9 176871
24 Micronutrients Phase 2,Phase 1
25 Nicotinic Acids Phase 2
26 Protein Kinase Inhibitors Phase 2,Phase 1
27 Trace Elements Phase 2,Phase 1
28 Vitamin B Complex Phase 2,Phase 1
29 Vitamins Phase 2,Phase 1
30 Alkylating Agents Phase 2
31 pancreatin Phase 2,Phase 1
32 Vaccines Phase 2,Phase 1
33 Adjuvants, Immunologic Phase 2
34 Freund's Adjuvant Phase 2
35 Folate Nutraceutical Phase 2,Phase 1
36 Vitamin B3 Nutraceutical Phase 2
37 Vitamin B9 Nutraceutical Phase 2,Phase 1
38 Cola Nutraceutical Phase 2,Phase 1
39
Cisplatin Approved Phase 1 15663-27-1 2767 441203 84093
40
Metronidazole Approved Phase 1 443-48-1 4173
41
Hyaluronic acid Approved, Vet_approved Phase 1 9004-61-9 53477741 24759
42
Fluorouracil Approved Phase 1 51-21-8 3385
43
Irinotecan Approved, Investigational Phase 1 97682-44-5, 100286-90-6 60838
44
Levoleucovorin Approved, Investigational Phase 1 68538-85-2
45
Azacitidine Approved, Investigational Phase 1 320-67-2 9444
46
leucovorin Approved, Nutraceutical Phase 1 58-05-9 143 6006
47
Camptothecin Experimental Phase 1 7689-03-4
48 Antiparasitic Agents Phase 1
49 Antiprotozoal Agents Phase 1
50 Antibodies Phase 1

Interventional clinical trials:

(show all 28)

# Name Status NCT ID Phase Drugs
1 Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
2 Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
3 Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
4 Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer Unknown status NCT00142480 Phase 2 Capecitabine;Oxaliplatin;Bevacizumab
5 Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer Completed NCT00361231 Phase 2 Bevacizumab;Gemcitabine;Oxaliplatin
6 A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts Completed NCT01007552 Phase 2 Gemcitabine, Capecitabine and Bevacizumab
7 A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC Completed NCT01267344 Phase 2 gemcitabine, oxaliplatin;cetuximab, gemcitabine, oxaliplatin
8 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT01093222 Phase 2 Erlotinib Hydrochloride;Sorafenib Tosylate
9 Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery Completed NCT00478140 Phase 2
10 S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT00238212 Phase 2 sorafenib tosylate
11 Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer Completed NCT00073905 Phase 2 capecitabine plus gemcitabine
12 S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT00033540 Phase 2 capecitabine;gemcitabine hydrochloride
13 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
14 Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder Terminated NCT00085410 Phase 2 bortezomib
15 Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract Terminated NCT00012246 Phase 2
16 Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery Withdrawn NCT01859182 Phase 2 selumetinib;Akt inhibitor MK2206
17 ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed by Surgery Completed NCT01825603 Phase 1 ADH-1;Cisplatin;Gemcitabine Hydrochloride
18 Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer Completed NCT00028496 Phase 1
19 Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer Completed NCT00544193 Phase 1 gemcitabine hydrochloride
20 Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer Completed NCT00987766 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin
21 RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
22 Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer Completed NCT00266097 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin;gemcitabine hydrochloride;Oxaliplatin
23 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
24 Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer Completed NCT00027534 Phase 1
25 Open-Label Study of PEGPH20 With CIS and GEM; PEGPH20 With Atezolizumab, CIS and GEM; and Compared With CIS and GEM Alone in HA-high Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangioc Recruiting NCT03267940 Phase 1 PEGylated Recombinant Human Hyaluronidase;Cisplatin;Gemcitabine;Atezolizumab
26 Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Active, not recruiting NCT01643499 Phase 1 oxaliplatin;irinotecan hydrochloride;leucovorin calcium;fluorouracil
27 Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Not yet recruiting NCT03257761 Phase 1 Guadecitabine
28 Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder Completed NCT00489515

Search NIH Clinical Center for Gallbladder Adenocarcinoma

Genetic Tests for Gallbladder Adenocarcinoma

Anatomical Context for Gallbladder Adenocarcinoma

MalaCards organs/tissues related to Gallbladder Adenocarcinoma:

38
Liver, Pancreas, Colon, Small Intestine, Lymph Node, Skin

Publications for Gallbladder Adenocarcinoma

Articles related to Gallbladder Adenocarcinoma:

(show top 50) (show all 90)
# Title Authors Year
1
Tumor Marker Kinetics as Prognosticators in Patients with Unresectable Gallbladder Adenocarcinoma Undergoing Palliative Chemotherapy. ( 29069888 )
2018
2
Spontaneous cholecystocutaneous fistula as a primary manifestation of gallbladder adenocarcinoma associated with gallbladder lithiasis - case report. ( 28730246 )
2017
3
Gallbladder Adenocarcinoma as the First Manifestation of Germline BRCA1 Mutation. ( 28785956 )
2017
4
Metastasis of gallbladder adenocarcinoma to the skin of the external auditory canal, a case report. ( 28522135 )
2017
5
Decision of surgical approach for advanced gallbladder adenocarcinoma based on a Bayesian network. ( 28876457 )
2017
6
Breast metastasis from recurrent gallbladder adenocarcinoma: a case report with review of the literature. ( 27512606 )
2016
7
Immunohistochemical expression of mucin antigens in gallbladder adenocarcinoma: MUC1-positive and MUC2-negative expression Is associated with vessel invasion and shortened survival. ( 27672051 )
2016
8
Diffusion-weighted magnetic resonance imaging of gallbladder adenocarcinoma: analysis with emphasis on histologic grade. ( 27133665 )
2016
9
Gallbladder adenocarcinoma and paraneoplastic parathyroid hormone mediated hypercalcemia. ( 27081650 )
2016
10
Cytokeratin 17 Expression is Associated With Poor Prognosis in Gallbladder Adenocarcinoma. ( 26990743 )
2016
11
Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naA^ve pT2 gallbladder adenocarcinoma patients. ( 26266900 )
2015
12
Surgical resection of solid gallbladder adenocarcinoma presenting as a large mass: report of a case. ( 25884804 )
2015
13
Dermatomyositis as the first manifestation of gallbladder adenocarcinoma: case report and literature overview. ( 25890241 )
2015
14
18F-FDG PET/CT Imaging of Gallbladder Adenocarcinoma - A Pictorial Review. ( 26430572 )
2015
15
Gallbladder neuroendocrine carcinoma: report of 10 cases and comparision of clinicopathologic features with gallbladder adenocarcinoma. ( 26339390 )
2015
16
BRMS1 and HPA as Progression, Clinical Biological Behaviors, and Poor Prognosis-related Biomarkers for Gallbladder Adenocarcinoma. ( 26200836 )
2015
17
Re: metastasis of gallbladder adenocarcinoma to Bauhin's valve: an extremely rare cause of intestinal obstruction. ( 25246829 )
2014
18
Prognostic Value of the Stem Cell Markers Epcam and CD133 Expression Of Gallbladder Adenocarcinoma. ( 26176038 )
2014
19
Gallbladder adenocarcinoma with sarcoid-like reaction in regional lymph nodes: report of a case. ( 25495692 )
2014
20
Overexpression of MTA1 and loss of KAI-1 and KiSS-1 expressions are associated with invasion, metastasis, and poor-prognosis of gallbladder adenocarcinoma. ( 25688501 )
2014
21
Histological phenotype is correlated with the wall-invasion pattern of gallbladder adenocarcinoma. ( 25355436 )
2014
22
Vitamin D receptor genetic variants are associated with susceptibility of gallbladder adenocarcinoma in a Chinese cohort. ( 25078595 )
2014
23
Lymph node status after resection for gallbladder adenocarcinoma: Prognostic implications of different nodal staging/scoring systems. ( 25312786 )
2014
24
Cutaneous metastasis of gallbladder adenocarcinoma in a patient with chronic lymphocytic leukemia: a case report and review of the literature. ( 23467457 )
2013
25
PSCA and Oct-4 expression in the benign and malignant lesions of gallbladder: implication for carcinogenesis, progression, and prognosis of gallbladder adenocarcinoma. ( 23984394 )
2013
26
Expression of p53 upregulated modulator of apoptosis (PUMA) and C-myb in gallbladder adenocarcinoma and their pathological significance. ( 23475628 )
2013
27
Correlation of S1P1 and ERp29 expression to progression, metastasis, and poor prognosis of gallbladder adenocarcinoma. ( 23558074 )
2013
28
Cheek metastasis from gallbladder adenocarcinoma. ( 23669176 )
2013
29
Clinicopathological features and CCT2 and PDIA2 expression in gallbladder squamous/adenosquamous carcinoma and gallbladder adenocarcinoma. ( 23782473 )
2013
30
Impact of adjuvant external beam radiotherapy on survival in surgically resected gallbladder adenocarcinoma: A propensity score-matched Surveillance, Epidemiology, and End Results analysis. ( 23876364 )
2013
31
Gastrointestinal Stromal Tumor with Synchronous Gallbladder Adenocarcinoma. ( 23749654 )
2013
32
Expression of Cell Cycle-Related Proteins, p16, p53 and p63 as Important Prognostic Markers in Gallbladder Adenocarcinoma. ( 24178677 )
2013
33
Secondary Sclerosing Cholangitis due to Gallbladder Adenocarcinoma. ( 23626514 )
2013
34
Antiproliferative and apoptosis-inducing activity of curcumin against human gallbladder adenocarcinoma cells. ( 23645731 )
2013
35
Coexistence of xanthogranulomatous cholecystitis and gallbladder adenocarcinoma: a fortuitous association? ( 24471194 )
2013
36
Immunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gallbladder adenocarcinoma. ( 23544944 )
2013
37
MTDH and EphA7 are markers for metastasis and poor prognosis of gallbladder adenocarcinoma. ( 21964981 )
2013
38
Expression of MUC1 and MUC4 in gallbladder adenocarcinoma. ( 23136569 )
2012
39
Gallbladder adenocarcinoma: evaluation of the prognostic factors in 100 resectable cases in Brazil. ( 22569972 )
2012
40
Identification of CD146 expression, angiogenesis, and lymphangiogenesis as progression, metastasis, and poor-prognosis related markers for gallbladder adenocarcinoma. ( 22076922 )
2012
41
Up-regulation of galectin-3 and Sambucus nigra agglutinin binding site is associated with invasion, metastasis and poor-progression of the gallbladder adenocarcinoma. ( 22497866 )
2012
42
Ala499Val (C>T) and Lys939Gln (A>C) polymorphisms of the XPC gene: their correlation with the risk of primary gallbladder adenocarcinoma--a case-control study in China. ( 21113018 )
2011
43
Mutations in the RAS/RAF/MAP kinase pathway commonly occur in gallbladder adenomas but are uncommon in gallbladder adenocarcinomas. ( 21307665 )
2011
44
Identification of PEG10 and TSG101 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma. ( 21455631 )
2011
45
Metastatic gallbladder adenocarcinoma with signet-ring cells: A case report. ( 21917161 )
2011
46
Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma. ( 21719208 )
2011
47
Giant gallbladder: adenocarcinoma complicated with empyema. ( 21217498 )
2011
48
Frequency of genetic alterations observed in cell cycle regulatory proteins and microsatellite instability in gallbladder adenocarcinoma: a translational perspective. ( 21545232 )
2011
49
Gallbladder adenocarcinoma with extended intramural spread in adenomyomatosis of the gallbladder with the pearl necklace sign. ( 21375832 )
2011
50
National trends in the management and survival of surgically managed gallbladder adenocarcinoma over 15 years: a population-based analysis. ( 20824371 )
2010

Variations for Gallbladder Adenocarcinoma

Expression for Gallbladder Adenocarcinoma

Search GEO for disease gene expression data for Gallbladder Adenocarcinoma.

Pathways for Gallbladder Adenocarcinoma

Pathways related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.08 EGFR ERBB2 SRC
2 12.05 EGFR ERBB2 SRC
3 11.91 EGFR ERBB2 SRC
4
Show member pathways
11.87 EGFR ERBB2 SRC
5
Show member pathways
11.84 EGFR ERBB2 SRC
6
Show member pathways
11.7 EGFR ERBB2 SRC
7 11.41 EGFR ERBB2 SRC
8 11.36 EGFR ERBB2 SRC
9
Show member pathways
11.27 EGFR ERBB2 SRC
10 11.27 EGFR ERBB2 SRC
11 11.13 EGFR SRC
12 11.12 EGFR SRC
13 11.09 EGFR MTDH
14 11.09 EGFR EPHA7 ERBB2 SRC
15 11.08 EGFR ERBB2 SRC
16 11.05 EGFR ERBB2
17 11.02 EGFR ERBB2
18 10.93 EGFR SRC
19 10.79 EGFR ERBB2 SRC
20 10.76 EGFR SRC
21 10.69 EGFR SRC

GO Terms for Gallbladder Adenocarcinoma

Biological processes related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 protein autophosphorylation GO:0046777 9.67 EGFR ERBB2 SRC
2 positive regulation of protein phosphorylation GO:0001934 9.65 EGFR EPHA7 ERBB2
3 peptidyl-tyrosine phosphorylation GO:0018108 9.62 EGFR EPHA7 ERBB2 SRC
4 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.61 EGFR EPHA7 ERBB2
5 liver regeneration GO:0097421 9.54 EGFR EZH2
6 cellular response to reactive oxygen species GO:0034614 9.52 EGFR SRC
7 regulation of cell motility GO:2000145 9.51 EGFR ERBB2
8 regulation of peptidyl-tyrosine phosphorylation GO:0050730 9.46 EGFR EPHA7
9 positive regulation of protein kinase B signaling GO:0051897 9.46 EGFR ERBB2 MTDH SRC
10 ERBB2 signaling pathway GO:0038128 9.43 EGFR ERBB2 SRC
11 negative regulation of ERBB signaling pathway GO:1901185 9.4 EGFR ERBB2
12 regulation of cell-cell adhesion GO:0022407 9.37 EPHA7 SRC
13 regulation of ERK1 and ERK2 cascade GO:0070372 9.13 EGFR EPHA7 ERBB2
14 positive regulation of MAP kinase activity GO:0043406 8.92 EGFR ERBB2 EZH2 SRC

Molecular functions related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.56 EGFR EPHA7 ERBB2 SRC
2 ephrin receptor binding GO:0046875 9.32 EPHA7 SRC
3 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.16 EGFR ERBB2
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 EGFR EPHA7 ERBB2
5 protein tyrosine kinase activity GO:0004713 8.92 EGFR EPHA7 ERBB2 SRC

Sources for Gallbladder Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....